Literature DB >> 3297068

The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.

Z H Siddik, D R Newell, F E Boxall, K R Harrap.   

Abstract

The plasma, urinary and biliary clearances of cisplatin and its non-nephrotoxic analogue, Carboplatin (cis-diammine-1,1-cyclobutane dicarboxylate platinum II, CBDCA, JM8) have been determined in mice and rats following intravenous administration of the compounds. The plasma concentration-time curves were biphasic during the time period studied (0-60 min), with t1/2 alpha of 2-3 min for both platinum complexes and t1/2 beta of 10-15 min for cisplatin and 25-26 min for Carboplatin. The kinetic rate constants, k12 and k21, were similar for both Carboplatin and cisplatin, indicating that there was no appreciable net accumulation of the compounds in the peripheral tissues. Immediately after administration, Carboplatin became reversibly bound to plasma proteins in vivo to the extent of about 20%. Appreciable irreversible binding appeared after the first 60 min and increased steadily, so that by 4 hr only 34% of the compound was present in the plasma as the free drug. In comparison, binding of cisplatin to plasma was exclusively irreversible and, after the first 10 min, free drug disappeared rapidly, such that by 60 min free platinum was not detectable. The plasma clearance of free cisplatin (26.1 ml/min/kg) was significantly greater than that of either Carboplatin (10.3 ml/min/kg) or insulin (10.1 ml/min/kg). The main route of excretion of the two platinum complexes was via the urine, with 80-90% of Carboplatin and 43-48% of cisplatin being excreted within 4 hr. In the rat, the Carboplatin excreted in the urine was predominantly as the unchanged compound. The renal clearance of cisplatin (12.3 ml/min/kg) was significantly greater than that of either Carboplatin (9.3 ml/min/kg) or insulin (9.6 ml/min/kg), suggesting that cisplatin was excreted by an active renal secretory mechanism whilst Carboplatin was eliminated by glomerular filtration alone. Biliary excretion of the two compounds was only 0.4-1.2% of the administered dose in 6 hr, with biliary clearance of cisplatin (0.27 ml/min/kg) being fivefold greater than that of Carboplatin (0.053 ml/min/kg). The results indicate that the major pharmacokinetic differences between Carboplatin and cisplatin relate to their renal handling and their reactivity with macromolecules. These differences may well underline the substantial lack of Carboplatin nephrotoxicity in comparison with cisplatin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297068     DOI: 10.1016/0006-2952(87)90490-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  31 in total

1.  Renal handling of carboplatin.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; J T Nielsen; L S Andersen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Cisplatin inhibition of anthrax lethal toxin.

Authors:  Mahtab Moayeri; Jason F Wiggins; Robin E Lindeman; Stephen H Leppla
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Formation of platinum (II) as a six member ring for sustained polymeric delivery.

Authors:  Sanjeewa N Senadheera; Ti Zhang; Chad E Groer; M Laird Forrest
Journal:  Eur J Med Chem       Date:  2017-05-06       Impact factor: 6.514

4.  Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse.

Authors:  F G King; R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

5.  Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Authors:  Xiang-Hong Peng; Yiqing Wang; Donghai Huang; Yuxiang Wang; Hyung Juc Shin; Zhengjia Chen; Michael B Spewak; Hui Mao; Xu Wang; Ying Wang; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-11-04       Impact factor: 15.881

6.  Intracellular metabolites of cisplatin in the rat kidney.

Authors:  P Mistry; C Lee; D C McBrien
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system.

Authors:  N Nishiyama; Y Kato; Y Sugiyama; K Kataoka
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

8.  Extracorporeal hemofiltration: a model for decreasing systemic drug exposure with intra-arterial chemotherapy.

Authors:  R A Graham; Z H Siddik; D C Hohn
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 9.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 10.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.